Amcasertib (BBI503)
Products
Description
Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.
Specifications
| Manufacturer Cat# | S8572 |
|---|---|
| Target | Stemness kinase |